The UK and US have reached a significant trade agreement that will guarantee zero levies on British drug shipments going into the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has committed to increase funding on medicines through the NHS. This pledge secures that import taxes on these vital goods will stay at zero for a period of three years.
This agreement comes after previous statements to hike tariffs on patented drug imports, with potential rates mentioned up to one hundred percent.
"This deal between the United Kingdom reinforces the international landscape for innovative medicines and introduces long-overdue balance to U.S.–U.K. pharmaceutical trade," a release noted.
Economic Importance
Pharmaceuticals are one of the Britain's biggest export categories to the America, which is clearly the biggest market for large UK drugmakers.
Export figures indicate that in the one-year period leading up to the third quarter, the UK shipped pharmaceutical products worth £11.1bn to the US. This amount made up a significant portion of total UK exports in that timeframe.
"This guarantee secures employment, boosts investment and facilitates the UK to establish itself as a international leader for medical research," the Business and Trade Secretary remarked.
Detailed NHS Changes
The agreement involves several notable changes from the British government:
- Price Threshold Increase: The UK will lift the affordability limit at which it deems new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a aim to increase total health service expenditure on medicines from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Payback Limit: The amount manufacturers must return to the NHS to stay within budget will be capped at 15%. Last year, repayments were more than twenty percent.
Industry Background
This agreement comes amid a long-running row between the drug companies and the British authorities over medicine costs and NHS adoption.
These tensions were heightened by assertions that American patients were paying significantly more for the identical medicines than consumers in the UK and Europe.
Recently, several large manufacturing plans in the UK have been paused or abandoned, while multi-billion-dollar investments have been announced toward projects in the United States.
One official acknowledged that the NHS must spend more on medicines, noting that its expenditure on drugs had decreased as a share of its overall budget over the past decade.
